SDC1 and neoplasm: We found that the combination therapy using the OC-46F2 anti Syndecan-1 blocking antibody and the immunocytokine L19-IL2 leads to a complete inhibition of tumor melanoma growth until day 90 from tumor implantation in 71% of treated mice.